During my years as a PhD student, I have had the pleasure of working with a number of amazing people.
First and foremost, my main supervisor Alex. Thank you for reading my thesis at 3 in the morning!!
But most of all, thank you for making these 5 (6? Who’s counting anyways) years so much fun, inspiring and educational. You have set the standard high for my future employers, and I hope that you will continue being my unofficial mentor :)
My co-supervisor Marie, you were the first to take me in to your lab and I am so happy you did!
You are an inspiring scientist (and a very positive/optimistic one, I must say), and working in your lab has been a joy from day one. Also, I truly appreciate you taking your time helping me with future science career plans.
I also want to take this opportunity to thank Lars K and Ingrid L for making floor 4 such a great and vibrant place to work at.
Former and present members of the MWH/Espinosa group: First of all, the little Espinosa crew: William, you make the perfect Espinosa lab member: smart, passionate about science and a little bit disorganized. Looking forward to read your TRIM28-paper ;) Alina, it’s been a pleasure having you at the lab. Good luck at your new job! (Also, I really, reeeeally miss your impeccable genotyping!!) To the rest of the MWH group: Amina, you are the backbone of this lab! And such a lovely, kind and sweet person. Vijole, thanks for always helping out, for baking wonderful cakes and for contributing so much to the great atmosphere at the lab. Nånnis, you are a little firecracker, so much fun! And a great scientist, you will do wonderful things I’m certain. (Also, have you named your daughter yet?!?) Aurélie, the French, not so French, yet very French French girl! We have to get a coffee soon (chocolate for you?) and talk about all the things I can’t miss in NYC! The MWH mama mafia: Sabrina, Gudny-Ella, Malin and Amanda. Sabrina, my office roomie and friend! I’m so glad to have had the opportunity to share office with you and talk about everything from kids, apartments, happy days, crappy days, to occasionally science ;) Gudny-Ella, multi-talented de luxe! Thanks for all the great party stories and all the fun! Malin, please work full-time at the lab again?! Then again, I might not be there :/ Thanks for being the super sweet YOU that you are! Amanda, how great that you had a baby almost at the exact same time as me
so that we could hang out more! Let’s plan for the next one?! *This is where I would have entered the emoji laughing so much that it’s crying*. Joanna, I always enjoy talking with you! Funny and smart! Marika, thank you so much for helping out with all the Sjögren patients for my projects.
And for bringing baklava now and then ;) Åse, we still miss you and your lovely stories! The super crew: Rita, thanks for Russian pancakes (yum), helping out with FACS when I had a meltdown at the lab, being super cool and so on :) Jorge, the scientist aka the DJ aka the traveler! Maybe you’re up next from the MWH group?! Keeping my fingers crossed for you! Nikos, hard-working is the one word (or is it two?) that describes you the best! I hope that you achieve all the things you work so hard for, you deserve it. Lauro, first thing that comes to mind: amazing tiramisu! Keep up all your good work! Lara M, you are brave, picking a high-risk project for your PhD. But those are also the fun ones! Good luck! Lara A, my BAFF-partner! Wishing you all the best in your future science career! Albin, what an intense start you had at the lab!! But it just turned out to prove that science fits you like a glove. Wishing you all the best! Vilija, Stina and Therese, come visit more often!
To all the former and present colleagues at the Rheumatology unit, thank you so much for all these years! I would especially like to thank: Lasse, thank you for introducing me to CMM!!
The rest of the HMGB-1 group, it’s lovely hearing your laughter through the hallway! Heidi, cell room for life! Julia, I will never forget our night at the infamous Patricia!! Joan, you’re up next!
You will rock!! Karin, my preggo/baby mama companion! Ferdinand, thanks for all the fun times!
Stina, Gunnel, Lillemor and all you lovely admin ladies, you have made my life so much easier.
Thank you!! Last but not least, Peter, my dear friend. Thank you for being you!
My office-buddies: Christina, Aase, Sabrina M, Sabrina R and Espen!
To my second lab family, the Neuroimmunology unit! Rasmus, Karl and Harald – We will always have Montenegro; Andre, my dear friend; Nada, sweet lovely Nada – Looking forward to a lifetime of friendship with you guys!
To the people that left the lab: Ame, Raphael Saadiq with you will go down in history! Alan, Canada, eh? Come back to visit soon! Mella, my superwoman! I’m so glad I got to know you and your family! Louise, miss you! Come hang out with me and Alexa!
“Gänget med hänget” – Mikkis, my long-time partner in crime. How could I ever have loaded a gel if it wasn’t for you?! Petra, my loud, lovely, cuddly hug bug! Pernilla, my funny, cool, fashion babe. Love you guys!!
My friends outside academia: Annika, Stella, Hanna, Fia. My girls – Forever and always! Love you!
And to my family, you’re everything! Mamma, thank you for helping out with Alexa and for supporting me through this – but most of all, thank you for being my role model and the first love of my life! David, my kind, smart and generous brother. Thank you for encouraging me to study science and for helping me with math all those times! Love you and your girls! Stefan and Rosanne, I wish you guys were closer, miss you and love you!
My little dream-team: Roham and Alexa, I can’t wait to see what the future holds for us! The two of you have my heart for life. I love you to the moon and back and then some!
Last but not least, thank you to all the patients who have contributed with invaluable samples for this work!
7. R
EFERENCES1. Nagano Y, Kojima Y. 1954. [Immunizing property of vaccinia virus inactivated by ultraviolets rays]. C R Seances Soc Biol Fil 148: 1700-2
2. Isaacs A, Lindenmann J. 1957. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147: 258-67
3. Rubinstein M, Rubinstein S, Familletti PC, Gross MS, Miller RS, Waldman AA, Pestka S.
1978. Human leukocyte interferon purified to homogeneity. Science 202: 1289-90 4. Taniguchi T, Fujii-Kuriyama Y, Muramatsu M. 1980. Molecular cloning of human
interferon cDNA. Proc Natl Acad Sci U S A 77: 4003-6
5. Mantei N, Schwarzstein M, Streuli M, Panem S, Nagata S, Weissmann C. 1980. The nucleotide sequence of a cloned human leukocyte interferon cDNA. Gene 10: 1-10 6. Silvennoinen O, Ihle JN, Schlessinger J, Levy DE. 1993. Interferon-induced nuclear
signalling by Jak protein tyrosine kinases. Nature 366: 583-5
7. Wilks AF. 1989. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A 86: 1603-7
8. Schindler C, Fu XY, Improta T, Aebersold R, Darnell JE, Jr. 1992. Proteins of
transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci U S A 89: 7836-9
9. Fu XY, Schindler C, Improta T, Aebersold R, Darnell JE, Jr. 1992. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci U S A 89: 7840-3
10. Darnell JE, Jr., Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional
activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-21
11. Aaronson DS, Horvath CM. 2002. A road map for those who don't know JAK-STAT.
Science 296: 1653-5
12. Decker T, Lew DJ, Mirkovitch J, Darnell JE, Jr. 1991. Cytoplasmic activation of GAF, an IFN-gamma-regulated DNA-binding factor. EMBO J 10: 927-32
13. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling.
Nat Rev Immunol 5: 375-86
14. Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Platanias LC. 2000. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 275: 27634-40
15. Platanias LC. 2003. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 98: 129-42
16. Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanias LC. 2002. Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 277: 14408-16
17. Nguyen H, Ramana CV, Bayes J, Stark GR. 2001. Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem 276: 33361-8
18. Wen Z, Darnell JE, Jr. 1997. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 25: 2062-7
19. Wen Z, Zhong Z, Darnell JE, Jr. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241-50
20. Trinchieri G. 2010. Type I interferon: friend or foe? J Exp Med 207: 2053-63
21. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C,
Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-5
22. Yoneyama M, Fujita T. 2009. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev 227: 54-65
23. Ishikawa H, Barber GN. 2008. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455: 674-8
24. Barber GN. 2015. STING: infection, inflammation and cancer. Nat Rev Immunol 15: 760-70
25. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339: 786-91
26. Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, Hayakawa Y, Hammond MC, Vance RE. 2013. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 3: 1355-61 27. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J,
Hornung V. 2013. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature 498: 380-4
28. Broz P, Monack DM. 2013. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol 13: 551-65
29. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity:
update on Toll-like receptors. Nat Immunol 11: 373-84
30. Colonna M, Trinchieri G, Liu YJ. 2004. Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-26
31. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T.
2005. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434: 1035-40
32. Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6: 644-58
33. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi T. 1988. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54: 903-13
34. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. 2003. Triggering the interferon antiviral response through an IKK-related pathway. Science 300: 1148-51 35. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ,
Liao SM, Maniatis T. 2003. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4: 491-6
36. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T. 2005. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434: 243-9
37. Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K, Matsuyama T, Taniguchi T, Honda K. 2005. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A 102: 15989-94
38. Lohoff M, Mak TW. 2005. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 5: 125-35
39. Zhao J, Kong HJ, Li H, Huang B, Yang M, Zhu C, Bogunovic M, Zheng F, Mayer L, Ozato K, Unkeless J, Xiong H. 2006. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J Biol Chem 281: 10073-80 40. Tamura T, Yanai H, Savitsky D, Taniguchi T. 2008. The IRF family transcription factors
in immunity and oncogenesis. Annu Rev Immunol 26: 535-84
41. Forster SC, Tate MD, Hertzog PJ. 2015. MicroRNA as Type I Interferon-Regulated Transcripts and Modulators of the Innate Immune Response. Front Immunol 6: 334 42. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ.
2013. Interferome v2.0: an updated database of annotated interferon-regulated genes.
Nucleic Acids Res 41: D1040-6
43. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32: 513-45
44. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-53
45. Nisole S, Stoye JP, Saib A. 2005. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3: 799-808
46. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-30
47. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells.
Cell 139: 499-511
48. Haller O, Kochs G, Weber F. 2006. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344: 119-30
49. Croker BA, Kiu H, Nicholson SE. 2008. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19: 414-22
50. Kawai T, Akira S. 2011. Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol Med 3: 513-27
51. Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, Jefferies CA. 2010. Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One 5:
e11776
52. Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. 2008. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 181: 1780-6 53. Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ. 2012. The E3 ubiquitin ligase TRIM21
negatively regulates the innate immune response to intracellular double-stranded DNA.
Nat Immunol 14: 172-8
54. Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Tailor P, Cho HK, Cheong J, Xiong H, Morse HC, 3rd, Ozato K. 2007. Cutting edge: autoantigen Ro52 is an
interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol 179: 26-30
55. Yoshimi R, Chang TH, Wang H, Atsumi T, Morse HC, 3rd, Ozato K. 2009. Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts. J Immunol 182: 7527-38
56. Lee-Kirsch MA. 2016. The Type I Interferonopathies. Annu Rev Med
57. Rodero MP, Crow YJ. 2016. Type I interferon-mediated monogenic autoinflammation:
The type I interferonopathies, a conceptual overview. J Exp Med 213: 2527-38
58. Crow YJ, Manel N. 2015. Aicardi-Goutieres syndrome and the type I interferonopathies.
Nat Rev Immunol 15: 429-40
59. Mok CC, Lau CS. 2003. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:
481-90
60. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. 2003.
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.
Proc Natl Acad Sci U S A 100: 2610-5
61. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. 2003.
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711-23
62. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. 2008. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 38: 2024-33
63. Lubbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, Rantapaa-Dahlqvist S, Verweij CL. 2013. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis 72: 776-80
64. Crow MK. 2014. Type I interferon in the pathogenesis of lupus. J Immunol 192: 5459-68 65. Ronnblom LE, Alm GV, Oberg KE. 1990. Possible induction of systemic lupus
erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227: 207-10
66. Niewold TB. 2008. Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol 14: 131-2
67. Niewold TB, Swedler WI. 2005. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 24: 178-81
68. Ronnblom L, Alm GV, Eloranta ML. 2009. Type I interferon and lupus. Curr Opin Rheumatol 21: 471-7
69. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. 2007. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity.
Nat Med 13: 543-51
70. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294: 1540-3
71. Ronnblom L, Pascual V. 2008. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17: 394-9
72. Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. 2005. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 52: 201-11 73. Cerutti A, Qiao X, He B. 2005. Plasmacytoid dendritic cells and the regulation of
immunoglobulin heavy chain class switching. Immunol Cell Biol 83: 554-62
74. Brito-Zeron P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M. 2016. Sjogren syndrome. Nat Rev Dis Primers 2: 16047
75. Oon S, Wilson NJ, Wicks I. 2016. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunology 5: e79
76. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W, investigators CDs. 2016. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75: 1909-16
77. Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis JC, Jr., Kennedy WP. 2016. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 75: 196-202
78. Kalunian KC. 2016. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells? Lupus 25: 1097-101
79. Parker BS, Rautela J, Hertzog PJ. 2016. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 16: 131-44
80. Verweij CL, Vosslamber S. 2013. Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Discov Med 15: 51-60
81. Guo B, Chang EY, Cheng G. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 118: 1680-90
82. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, Verweij CL. 2006. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 7: 522-31
83. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. 2008. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3: e1927
84. Jonasch E, Haluska FG. 2001. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34-55
85. Ronnblom L, Eloranta ML. 2013. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 25: 248-53
86. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, Brohawn P, Kiener PA, Richman L, Fiorentino D, Greenberg SA, Jallal B, Yao Y. 2011. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 70: 2029-36
87. Fang TC, Schaefer U, Mecklenbrauker I, Stienen A, Dewell S, Chen MS, Rioja I,
Parravicini V, Prinjha RK, Chandwani R, MacDonald MR, Lee K, Rice CM, Tarakhovsky A. 2012. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med 209: 661-9
88. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, Sun Q, Wang K, Ba Y, Wang Q, Wang D, Yang J, Liu P, Xu T, Yan Q, Zhang J, Zen K, Zhang CY. 2010.
Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 39:
133-44
89. Ronnblom L. 2016. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol 34: 21-4
90. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. 2007. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely.
Proc Natl Acad Sci U S A 104: 7080-5
91. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, Rajewsky K. 2007. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131: 146-59
92. Rodriguez-Pla A, Patel P, Maecker HT, Rossello-Urgell J, Baldwin N, Bennett L, Cantrell V, Baisch J, Punaro M, Gotte A, Nassi L, Wright T, Palucka AK, Banchereau J, Pascual V. 2014. IFN priming is necessary but not sufficient to turn on a migratory dendritic cell program in lupus monocytes. J Immunol 192: 5586-98
93. Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T. 1999. Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J 18: 5028-41
94. Murphy PT, Fennelly DF, Stuart M, O'Donnell JR. 1990. Alfa-interferon in a case of hypereosinophilic syndrome. Br J Haematol 75: 619-20
95. Cogan E, Roufosse F. 2012. Clinical management of the hypereosinophilic syndromes.
Expert Rev Hematol 5: 275-89; quiz 90
96. Forster S. 2012. Interferon signatures in immune disorders and disease. Immunol Cell Biol 90: 520-7
97. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1: 519-25
98. Kirtava Z, Blomberg J, Bredberg A, Henriksson G, Jacobsson L, Manthorpe R. 1995.
CD4+ T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjogren's syndrome. Clin Exp Rheumatol 13: 609-16
99. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin-Goguet F, Mothes W, Hazan U, Transy C, Pancino G, Nisole S. 2009. Human TRIM gene expression in response to interferons. PLoS One 4: e4894
100. Woo SJ, Im J, Jeon JH, Kang SS, Lee MH, Yun CH, Moon EY, Song MK, Kim HH, Han SH. 2013. Induction of BAFF expression by IFN-gamma via JAK/STAT signaling pathways in human intestinal epithelial cells. J Leukoc Biol 93: 363-8
101. Sanz I, Yasothan U, Kirkpatrick P. 2011. Belimumab. Nat Rev Drug Discov 10: 335-6 102. Deguchi Y, Hara H, Negoro S, Kakunaga T, Kishimoto S. 1987. Protooncogene
expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus as an indicator of the disease activity. Clin Immunol Immunopathol 45: 424-39 103. Boumpas DT, Tsokos GC, Mann DL, Eleftheriades EG, Harris CC, Mark GE. 1986.
Increased proto-oncogene expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 29: 755-60 104. Ramsay RG, Gonda TJ. 2008. MYB function in normal and cancer cells. Nat Rev Cancer 8:
523-34
105. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. 2015. Type I interferons in anticancer immunity. Nat Rev Immunol 15: 405-14
106. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. 2006.
Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65: 796-803
107. Yanagisawa H, Nagasawa T, Kuramochi S, Abe T, Ikawa Y, Todokoro K. 1991.
Constitutive expression of exogenous c-myb gene causes maturation block in monocyte-macrophage differentiation. Biochim Biophys Acta 1088: 380-4
108. Zhao L, Ye P, Gonda TJ. 2014. The MYB proto-oncogene suppresses monocytic differentiation of acute myeloid leukemia cells via transcriptional activation of its target gene GFI1. Oncogene 33: 4442-9
109. Shoshan Y, Shapira I, Toubi E, Frolkis I, Yaron M, Mevorach D. 2001. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. J Immunol 167: 5963-9
110. Zawada AM, Zhang L, Emrich IE, Rogacev KS, Krezdorn N, Rotter B, Fliser D, Devaux Y, Ziegler-Heitbrock L, Heine GH. 2016. MicroRNA profiling of human intermediate monocytes. Immunobiology
111. Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, Horvath L, Wallerskog T, Oukka M, Nyberg F, Kuchroo VK, Wahren-Herlenius M. 2006. The Sjogren's
syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 176: 6277-85
112. Espinosa A, Hennig J, Ambrosi A, Anandapadmanaban M, Abelius MS, Sheng Y, Nyberg F, Arrowsmith CH, Sunnerhagen M, Wahren-Herlenius M. 2011. Anti-Ro52
autoantibodies from patients with Sjogren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem 286: 36478-91
113. Espinosa A, Oke V, Elfving A, Nyberg F, Covacu R, Wahren-Herlenius M. 2008. The autoantigen Ro52 is an E3 ligase resident in the cytoplasm but enters the nucleus upon cellular exposure to nitric oxide. Exp Cell Res 314: 3605-13